This Article Full Text Full Text (PDF) All Versions of this Article: 40/2/604    most recent STROKEAHA.108.522409v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Simard, J. M. Articles by Gerzanich, V. Search for Related Content PubMed PubMed Citation Articles by Simard, J. M. Articles by Gerzanich, V. Related Collections Animal models of human disease Acute Cerebral Infarction Neuroprotectors

(Stroke. 2009;40:604.)
© 2009 American Heart Association, Inc.

Original Contributions

Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke

J. Marc Simard, MD, PhD; Vladimir Yurovsky, PhD; Natalia Tsymbalyuk, MS; Ludmila Melnichenko, MS; Svetlana Ivanova, PhD Volodymyr Gerzanich, MD, PhD

From the Departments of Neurosurgery (J.M.S., V.Y., N.T., L.M., S.I., V.G.), Physiology (J.M.S.), and Pathology (J.M.S.), University of Maryland School of Medicine, Baltimore, Md.

Correspondence to J. Marc Simard, Department of Neurosurgery, 22 S. Greene Street, Suite S-12-D, Baltimore, MD 21201-1595. E-mail msimard{at}smail.umaryland.edu

Background and Purpose— Ischemia/hypoxia induces de novo expression of the sulfonylurea receptor 1-regulated NC(Ca-ATP) channel. In rodent models of ischemic stroke, early postevent administration of the sulfonylurea, glibenclamide, is highly effective in reducing edema, mortality, and lesion volume, and in patients with diabetes presenting with ischemic stroke, pre-event plus postevent use of sulfonylureas is associated with better neurological outcome. However, the therapeutic window for treatment with glibenclamide has not been studied.

Methods— We examined the effect of low-dose (nonhypoglycemogenic) glibenclamide in 3 rat models of ischemic stroke, all involving proximal middle cerebral artery occlusion (MCAo): a thromboembolic model, a permanent suture occlusion model, and a temporary suture occlusion model with reperfusion (105 minutes occlusion, 2-day reperfusion). Treatment was started at various times up to 6 hours post-MCAo. Lesion volumes were measured 48 hours post-MCAo using 2,3,5-triphenyltetrazolium chloride.

Results— Glibenclamide reduced total lesion volume by 53% in the thromboembolic MCAo model at 6 hours, reduced corrected cortical lesion volume by 51% in the permanent MCAo model at 4 hours, and reduced corrected cortical lesion volume by 41% in the temporary MCAo model at 5.75 hours (P<0.05 for all 3). Analysis of pooled data from the permanent MCAo and temporary MCAo series indicated a sigmoidal relationship between hemispheric swelling and corrected cortical lesion volume with the half-maximum cortical lesion volume being observed with 10% hemispheric swelling.

Conclusions— Low-dose glibenclamide has a strong beneficial effect on lesion volume and has a highly favorable therapeutic window in several models of ischemic stroke.

Supplemental Methods